Summary of "IVUS/OCT stent guidance, pre- and post-stenting"

Main ideas / lessons

Evidence and trial outcomes (conceptual summary)

Imaging methodology and endpoints (detailed bullet workflow)

A) Pre-stenting: define lesion severity and reference zones

  1. Define the measurement framework

    • Stenosis severity is based on lumen-to-lumen:
      • Compare lumen diameter at the stenosis vs lumen diameter at a reference segment.
    • Do not define stenosis severity by comparing stenosis lumen to external elastic membrane / vessel size (speaker emphasis).

  2. Define reference zones (critical concept)

    • Reference zone definition involves plaque burden:
      • Black burden < 50% = an ideal reference.
      • Black burden > 50% often indicates plaque burden that is not hemodynamically significant, but it is not an ideal “healthy landing zone.”

  3. Choose an endpoint-driven stent landing strategy

    • Prefer to end the stent in healthier tissue:
      • Target: plaque burden < 50% at landing zones.
    • If heavy diffuse plaque prevents nearby segments with <50% black burden, landing may involve >50% black burden to avoid excessively long stents.

  4. Stenosis “when to stent” concept

    • Imaging alone has imperfect correlation with functional significance.
    • Preferred decision tool: FFR/IFR.
    • Imaging-assisted criteria mentioned:
      • Black burden > 70% at lesion site and MLA < 2.75–3.0 mm² (speaker notes a related cutoff around ~2.5–3.0 mm²).
    • However, no imaging cutoff reliably equals physiologic significance, hence physiologic testing is preferred.

B) Stent sizing (how to select diameter/length targets)

  1. Core warning

    • Do not size the stent based on the external elastic membrane (EEM) at the lesion site.
    • Rationale: positive remodeling can make EEM larger → sizing to it risks oversizing and increasing edge dissections/perforations.

  2. Two standard sizing approaches (speaker’s options)

    • Distal reference lumen method (1:1)

      • Size the stent to 100% of the distal reference lumen (or reference lumen diameter).
      • Mentioned as used in landmark/early trials (speaker references MUSIC, ULTIMATE, and iOS/other studies).

    • EEM-based method with downsizing

      • When using EEM/external elastic membrane:
        • Downsize by ~0.25 mm.
      • Rationale: when plaque is higher, the EEM-to-lumen discrepancy grows; downsizing reduces risk of edge dissections and overly aggressive sizing.

  3. Practical OCT reference limitation

    • OCT has limited depth, and lipid causes shadowing, so EEM may be hard to visualize.
    • OCT workaround for reference selection (as described for OCT trial practice):
      • Choose a reference with best-looking lumen, or where luminal stenosis < 30% vs best lumen.
      • The reference lumen should not be more than 30% obstructive compared to the best lumen.

C) Post-stenting imaging: expansion targets (the “must hit” endpoint)

  1. Expansion assessment uses lumen reference values

    • Evaluate minimal stent area (MSA) vs reference lumen (not EEM).
    • “Well-expanded” criteria:
      • MSA > 90% of distal reference lumen area, or
      • MSA > 80% of average proximal + distal reference lumen areas

  2. Absolute MSA alternatives

    • Both major trials allowed absolute targets:
      • Non-left-main MSA > 5.5 mm²
      • Left main MSA > 7.0 mm² distal and > 8.0 mm² proximal
    • Speaker preference: relative targets (more physiologically grounded).

  3. Special situations: long stents / large bifurcations

    • For long stents (>28–30 mm) and/or stents across large bifurcations:
      • Assess proximal and distal separately:
        • Proximal: proximal minimal stent area > 90% of proximal reference lumen
        • Distal: distal minimal stent area > 90% of distal reference lumen
      • Purpose: account for vessel size change across the segment.

D) Post-stenting imaging: edge-related targets (additional endpoints)

The speaker describes three main targets (with an optional less important fourth):

  1. Edge dissection

    • Consider “significant” only if:
      • Dissection extends deep to the media, and is either:
        • Length > 3 mm, or
        • Width > 60 degrees
    • Shallow intimal-only dissections:
      • Even if long/wide, if they don’t reach the media, they did not warrant further therapy in major trials.
    • Speaker notes OCT detects more minor dissections, reinforcing use of trial-grade definitions.

  2. Edge disease

    • Trial logic described:
      • Ideal: edge black burden < 50%
      • If residual plaque burden is >50% at edges, it is suboptimal
    • Management approach (speaker’s claims):
      • ULTIMATE: repeat ballooning using an undersized balloon; no extra stenting as recommended.
      • RENOVATE: repeat ballooning not required / additional stenting not recommended depending on protocol.

  3. Edge “do not overtreat” principle (speaker’s pitfalls)

    • Warning against ballooning or additional stenting based only on easy numbers such as:
      • Edge lumen area < 4 mm²
      • Or applying residual plaque criteria too liberally
    • Rationale: neoatherosclerosis / ISR-like biology at stented edges may be more aggressive than progression of native moderate disease.
    • Speaker argues: stenting moderate edge disease is not beneficial and can worsen outcomes (higher TLR at 1 year; continuing attrition thereafter).

  4. Stent malapposition (least important/less consistent predictor)

    • “Major malapposition” definition in RENOVATE/other trial language:
      • Gap > 0.4 mm between stent and vessel wall
    • Speaker stance: malapposition is easily seen but not consistently linked to long-term events; focus should remain on expansion and appropriate edge management.

E) Post-dilation: deciding balloon sizing and technique

  1. If under-expanded → post-dilate

    • Use a non-compliant balloon
    • Inflation pressure: >18 atmospheres (speaker threshold)

  2. Balloon sizing rule depends on reference type

    • If sizing from EEM:
      • Balloon size based on EEM measurement rounded down
    • If sizing from lumen:
      • Balloon size based on lumen reference rounded up (speaker: up to 0.5 mm in some cases)

  3. Tapering / bifurcation situations

    • With natural taper:
      • Distally size based on distal EEM/lumen
      • Proximally size based on proximal EEM/lumen
    • Examples align with OCT trial practices described by the speaker.

Pitfalls and why ILLUMINA 4 failed (as argued by the speaker)

A) Over-treatment at edges due to liberal thresholds

B) More procedure time and higher resource exposure (correlated, not necessarily root cause)

C) “Don’t eyeball it”—measurement discipline required

D) Contrast with another OCT positive trial

Final takeaway

Speakers / sources featured

Speaker (as identified from the narration)

Trials / studies cited

Notable imaging/clinical metrics and decision tools referenced

Category ?

Educational

Share this summary

Is the summary off?

If you think the summary is inaccurate, you can reprocess it with the latest model.

Summarize another video

Video